Opthea Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPT research report →
Companywww.opthea.com
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases.
- CEO
- Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,
- IPO
- 2020
- Employees
- 33
- HQ
- South Yarra, VIC, AU
Price Chart
Valuation
- Market Cap
- $4.24B
- P/E
- -2.16
- P/S
- 2432.54
- P/B
- -2.63
- EV/EBITDA
- -3.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -61041.59%
- Net Margin
- -101412.03%
- ROE
- 132.37%
- ROIC
- -307.98%
Growth & Income
- Revenue
- $38.36K · -69.23%
- Net Income
- $-250,000,000 · -13.51%
- EPS
- $0.00 · 100.00%
- Op Income
- $-239,000,000
- FCF YoY
- -50.89%
Performance & Tape
- 52W High
- $6.30
- 52W Low
- $1.79
- 50D MA
- $4.37
- 200D MA
- $3.53
- Beta
- 1.67
- Avg Volume
- 32.32K
Get TickerSpark's AI analysis on OPT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 6, 06 | HARROLD JASON M | sell | 784 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 15,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 785 |
| Mar 6, 06 | HARROLD JASON M | sell | 7,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 11,250 |
| Mar 6, 06 | HARROLD JASON M | sell | 22,500 |
| Mar 6, 06 | HARROLD JASON M | sell | 125,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 25,000 |
| Mar 6, 06 | HARROLD JASON M | sell | 45,000 |
Our OPT Coverage
We haven't published any research on OPT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate OPT Report →